Revelation Biosciences, Inc. (REVB)

Compare

2.6700

+0.0400

+(1.52%)

At close: April 2 at 4:00:00 PM EDT

2.4500

-0.22

(-8.24%)

After hours: April 2 at 7:12:52 PM EDT

REVB Announces Positive Test Results

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl

Zacks Small Cap Research 16 days ago

REVBW
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

SAN DIEGO, March 17, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells (PBMCs) exposed to clinically relevant promoter molecules of inflammation. Revelation anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1b

Business Wire 16 days ago

REVB
+1.52%
REVBW
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

SAN DIEGO, March 13, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation’s Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.

Business Wire 20 days ago

REVB
+1.52%
REVBW
REVB Starts 2025 With Bright Future Ahead

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl

Zacks Small Cap Research 26 days ago

REVBW
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

SAN DIEGO, March 06, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results.

Business Wire 27 days ago

REVB
+1.52%
REVBW
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

SAN DIEGO, February 26, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced dosing of the first patient in the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of intravenous single ascending doses of Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The US-based, multi-site, placebo-controlled study will enr

Business Wire last month

REVB
+1.52%
REVBW
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

SAN DIEGO, February 24, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the Nasdaq Stock Market LLC ("Nasdaq") formally notified the Company that REVB common stock will continue to be listed and traded on Nasdaq, as Revelation is in compliance with all requirements for continued listing.

Business Wire last month

REVB
+1.52%
REVBW
REVB Start 1B Trial and Announces Split

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) announced that it has initiated its US based Phase 1b clinical study to evaluate the potential of Gemini as a preconditioning treatment in patients with chronic kidney disease (CKD). This is extremely good news for the progression of this important treatment that has showed so much promise in

Zacks Small Cap Research 2 months ago

REVBW
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

SAN DIEGO, January 24, 2025--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2025. The reverse stock split will be effective as of the morning of January 28, 2025, and the Company’s common stock will trade on a post-split basis at the beginning of trading on the same date under

Business Wire 2 months ago

REVB
+1.52%
REVBW
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

SAN DIEGO, January 21, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that it has started its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The US based multi-site placeb

Business Wire 2 months ago

REVB
+1.52%
REVBW
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

SAN DIEGO, January 13, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franc

Business Wire 2 months ago

REVB
+1.52%
REVBW
Nasdaq Grants Revelation Biosciences Inc. Continued Listing

SAN DIEGO, January 06, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the Nasdaq Hearings Panel issued a decision letter granting Revelation’s request to continue its listing on The Nasdaq Stock Market, subject to its stock trading at or above $1.00 for at least ten consecutive trading days by February 14, 2025.

Business Wire 2 months ago

REVB
+1.52%
REVBW
Sector Update: Health Care Stocks Mixed Late Afternoon

Health care stocks were mixed in late Tuesday afternoon trading with the NYSE Health Care Index addi

PREMIUM
MT Newswires 3 months ago

JANX

REVBW

CYTK
Top Midday Decliners

Revelation Biosciences (REVB) said Tuesday it entered into a definitive agreement for the immediate

PREMIUM
MT Newswires 3 months ago

INTC

REVBW
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

SAN DIEGO, December 03, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,064,040 shares of common stock, issued by the Company on August 22, 2024 (the "Existing Warrants"), at the exercise

Business Wire 3 months ago

REVB
+1.52%
REVBW
REVB Gets FDA Go Ahead

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted the company’s IND application for Gemini. This announcement allows the Company to initiate its US based Phase 1b clinical study to evaluate the potential of Gemini as a preconditioning treatment in patients with chronic kidney disease (CKD). This is

Zacks Small Cap Research 3 months ago

REVBW
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

SAN DIEGO, December 02, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the United States Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for Gemini. This game changing milestone allows the Company to initiate its US based Phase 1b clinical study to evaluate the poten

Business Wire 3 months ago

REVB
+1.52%
REVBW
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

SAN DIEGO, November 12, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced it has successfully completed the GMP manufacture of Gemini drug product to support anticipated clinical studies in the United States. GMP compliant manufacturing of Gemini is a pivotal requirement for an Investigational New Drug (IND) a

Business Wire 4 months ago

REVB
+1.52%
REVBW
REVB Results Set Stage for Future Growth

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) announced its 3Q2024 financial results which showed, after exciting testing announcements detailed below, good cash on hand that the company says is at least enough to finance operations into 2025. Clinical stage companies are often in a cash crunch, and we are pleased to see that Revelation

Zacks Small Cap Research 4 months ago

REVBW
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

SAN DIEGO, November 08, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results.

Business Wire 4 months ago

REVB
+1.52%
REVBW

Performance Overview

Return	REVB	S&P 500 (^GSPC)
YTD	-63.80%	-3.58%
1-Year	-93.56%	+8.94%
3-Year	-99.99%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Revelation Biosciences, Inc. (REVB)

REVB Announces Positive Test Results

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

REVB Starts 2025 With Bright Future Ahead

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

REVB Start 1B Trial and Announces Split

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Sector Update: Health Care Stocks Mixed Late Afternoon

Top Midday Decliners

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

REVB Gets FDA Go Ahead

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

REVB Results Set Stage for Future Growth

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Performance Overview